Anakinra
Kineret (anakinra) is a protein pharmaceutical. Anakinra was first approved as Kineret on 2001-11-14. It is used to treat cryopyrin-associated periodic syndromes and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-1 receptor type 1.
| Trade Name | Kineret |
|---|---|
| Common Name | Anakinra |
| Indication | cryopyrin-associated periodic syndromes, rheumatoid arthritis |
| Drug Class | Interleukin-1 (IL-1) receptor antagonists |
